search
Back to results

Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections

Primary Purpose

Gonorrhea, Sexually Transmitted Infection

Status
Recruiting
Phase
Phase 3
Locations
Hong Kong
Study Type
Interventional
Intervention
4CMenB vaccine
Placebo
Sponsored by
Chinese University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Gonorrhea

Eligibility Criteria

18 Years - 50 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria: Male adult who has had sex with another male in the past six months Ages 18 years or above Normally resides in Hong Kong Able to communicate in written and spoken Chinese or English At risk of gonorrhoea infection (had condomless sex with more than one man within the last six months, history of STI diagnosis, inclination to have condomless sex, and other PrEP-eligible criteria) Negative NG test result at the time of recruitment No history of previous vaccination with MenB vaccines Able and willing to attend all study visits Exclusion Criteria: Contraindications to receive MenB vaccine Unable to give informed consent

Sites / Locations

  • Stanley Ho Centre for Emerging Infectious DiseasesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Intervention

Control

Arm Description

Intramuscular injection of 2 doses of 0.5mL 4CMenB vaccine 1 month apart

Intramuscular injection of 2 doses of 0.5mL placebo 1 month apart

Outcomes

Primary Outcome Measures

Comparison between incidence of NG between two groups
Difference in NG incidences in the two groups

Secondary Outcome Measures

Changes in risk behaviours and networking pattern after vaccination
Frequency of sex networking, number of sex partners, and use of condoms
Safety profile of the vaccine
Prevalence of adverse events

Full Information

First Posted
March 1, 2023
Last Updated
May 13, 2023
Sponsor
Chinese University of Hong Kong
search

1. Study Identification

Unique Protocol Identification Number
NCT05766904
Brief Title
Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections
Official Title
Efficacy of a Meningococcal B Vaccine Against Neisseria Gonorrhoeae Infections Among Men Who Have Sex With Men: a Randomised-controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 4, 2023 (Actual)
Primary Completion Date
March 2025 (Anticipated)
Study Completion Date
September 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Objectives: Efficacy of a meningococcal vaccine against Neisseria gonorrhoea (NG) infection among men who have sex with men (MSM). Design: Parallel randomised double-blind placebo-controlled trial. Setting: A teaching hospital in Hong Kong. Participants: 150 adult MSM at risk of gonorrhoea infection (condomless sex with more than one man within the last six months, history of sexually transmitted infection [STI] diagnosis, inclination to have condomless sex, and other PrEP-eligible criteria) would be recruited into the trial, with half allocated to intervention and control group each. Intervention: Intervention and control group would receive, one month apart, two doses of meningococcal vaccine and normal saline, respectively. Main outcome measures: Safety and efficacy of vaccine against gonorrhoea (time to first gonorrhoea infection and incidence), and behavioural change after vaccination. Expected results: NG incidences in two groups would be compared. Efficacy of vaccine against gonorrhoea would be determined after controlling confounding variables. Characteristics of participants with incident NG would be distinguished from those without incident infections. Change of frequency of sexual activities and networking would be noted. Implications: Strategies on STI screening and vaccination could be informed. Reduced STI burden post-vaccination could be measured with surveillance system.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gonorrhea, Sexually Transmitted Infection

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Participants in the vaccination group would receive two doses of 4CMenB vaccine 1 month apart (at Month 0 and Month 1) while subjects in the control group would receive two doses of normal saline of a similar volume.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Block randomisation would be used to generate the list of treatment groups with a block size of 4 in a centralised computer by a staff in the Research Centre unrelated to data analysis. Group assignment would be concealed and performed by another staff unrelated to data analysis who will pick the group number from the random allocation sequence in sequential order. The subjects and investigators would therefore be blinded.
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Intramuscular injection of 2 doses of 0.5mL 4CMenB vaccine 1 month apart
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Intramuscular injection of 2 doses of 0.5mL placebo 1 month apart
Intervention Type
Biological
Intervention Name(s)
4CMenB vaccine
Other Intervention Name(s)
Bexsero
Intervention Description
Four-component MenB vaccine
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
0.9% Sodium Chloride Inj. B.P.
Primary Outcome Measure Information:
Title
Comparison between incidence of NG between two groups
Description
Difference in NG incidences in the two groups
Time Frame
Month 2 to Month 24
Secondary Outcome Measure Information:
Title
Changes in risk behaviours and networking pattern after vaccination
Description
Frequency of sex networking, number of sex partners, and use of condoms
Time Frame
Month 2 to Month 24
Title
Safety profile of the vaccine
Description
Prevalence of adverse events
Time Frame
Month 2 to Month 24

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male adult who has had sex with another male in the past six months Ages 18 years or above Normally resides in Hong Kong Able to communicate in written and spoken Chinese or English At risk of gonorrhoea infection (had condomless sex with more than one man within the last six months, history of STI diagnosis, inclination to have condomless sex, and other PrEP-eligible criteria) Negative NG test result at the time of recruitment No history of previous vaccination with MenB vaccines Able and willing to attend all study visits Exclusion Criteria: Contraindications to receive MenB vaccine Unable to give informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Secretariat
Phone
22528812
Email
ceid@med.cuhk.edu.hk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tsz Ho Kwan, PhD
Organizational Affiliation
Jockey Club School of Public Health and Primary Care
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanley Ho Centre for Emerging Infectious Diseases
City
Sha Tin
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Secretariat
Phone
+85222528812
Email
ceid@med.cuhk.edu.hk
First Name & Middle Initial & Last Name & Degree
Tsz Ho Kwan, PhD
First Name & Middle Initial & Last Name & Degree
Ngai Sze Wong, PhD
First Name & Middle Initial & Last Name & Degree
Pui Chung Denise Chan, PhD
First Name & Middle Initial & Last Name & Degree
Shui Shan Lee, FRCP

12. IPD Sharing Statement

Learn more about this trial

Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections

We'll reach out to this number within 24 hrs